Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,401
archived clinical trials in
Alzheimer Disease

ADvance DBS-f in Patients With Mild Probable Alzheimer's Disease
A Twelve Month Double-blind Randomized Controlled Feasibility Study to Evaluate the Safety, Efficacy and Tolerability of Deep Brain Stimulation of the Fornix (DBS-f) in Patients With Mild Probable Alzheimer's Disease
Status: Enrolling
Updated:  10/27/2015
Banner Research Institute at Sun City
mi
from
Sun City, AZ
ADvance DBS-f in Patients With Mild Probable Alzheimer's Disease
A Twelve Month Double-blind Randomized Controlled Feasibility Study to Evaluate the Safety, Efficacy and Tolerability of Deep Brain Stimulation of the Fornix (DBS-f) in Patients With Mild Probable Alzheimer's Disease
Status: Enrolling
Updated: 10/27/2015
Banner Research Institute at Sun City
mi
from
Sun City, AZ
Click here to add this to my saved trials
ADvance DBS-f in Patients With Mild Probable Alzheimer's Disease
A Twelve Month Double-blind Randomized Controlled Feasibility Study to Evaluate the Safety, Efficacy and Tolerability of Deep Brain Stimulation of the Fornix (DBS-f) in Patients With Mild Probable Alzheimer's Disease
Status: Enrolling
Updated:  10/27/2015
University of Florida Gainesville
mi
from
Gainesville, FL
ADvance DBS-f in Patients With Mild Probable Alzheimer's Disease
A Twelve Month Double-blind Randomized Controlled Feasibility Study to Evaluate the Safety, Efficacy and Tolerability of Deep Brain Stimulation of the Fornix (DBS-f) in Patients With Mild Probable Alzheimer's Disease
Status: Enrolling
Updated: 10/27/2015
University of Florida Gainesville
mi
from
Gainesville, FL
Click here to add this to my saved trials
ADvance DBS-f in Patients With Mild Probable Alzheimer's Disease
A Twelve Month Double-blind Randomized Controlled Feasibility Study to Evaluate the Safety, Efficacy and Tolerability of Deep Brain Stimulation of the Fornix (DBS-f) in Patients With Mild Probable Alzheimer's Disease
Status: Enrolling
Updated:  10/27/2015
Johns Hopkins Bayview
mi
from
Baltimore, MD
ADvance DBS-f in Patients With Mild Probable Alzheimer's Disease
A Twelve Month Double-blind Randomized Controlled Feasibility Study to Evaluate the Safety, Efficacy and Tolerability of Deep Brain Stimulation of the Fornix (DBS-f) in Patients With Mild Probable Alzheimer's Disease
Status: Enrolling
Updated: 10/27/2015
Johns Hopkins Bayview
mi
from
Baltimore, MD
Click here to add this to my saved trials
ADvance DBS-f in Patients With Mild Probable Alzheimer's Disease
A Twelve Month Double-blind Randomized Controlled Feasibility Study to Evaluate the Safety, Efficacy and Tolerability of Deep Brain Stimulation of the Fornix (DBS-f) in Patients With Mild Probable Alzheimer's Disease
Status: Enrolling
Updated:  10/27/2015
Hospital of the University of Pennsylvania: Penn Memory Clinic
mi
from
Philadelphia, PA
ADvance DBS-f in Patients With Mild Probable Alzheimer's Disease
A Twelve Month Double-blind Randomized Controlled Feasibility Study to Evaluate the Safety, Efficacy and Tolerability of Deep Brain Stimulation of the Fornix (DBS-f) in Patients With Mild Probable Alzheimer's Disease
Status: Enrolling
Updated: 10/27/2015
Hospital of the University of Pennsylvania: Penn Memory Clinic
mi
from
Philadelphia, PA
Click here to add this to my saved trials
ADvance DBS-f in Patients With Mild Probable Alzheimer's Disease
A Twelve Month Double-blind Randomized Controlled Feasibility Study to Evaluate the Safety, Efficacy and Tolerability of Deep Brain Stimulation of the Fornix (DBS-f) in Patients With Mild Probable Alzheimer's Disease
Status: Enrolling
Updated:  10/27/2015
Brown University
mi
from
Providence, RI
ADvance DBS-f in Patients With Mild Probable Alzheimer's Disease
A Twelve Month Double-blind Randomized Controlled Feasibility Study to Evaluate the Safety, Efficacy and Tolerability of Deep Brain Stimulation of the Fornix (DBS-f) in Patients With Mild Probable Alzheimer's Disease
Status: Enrolling
Updated: 10/27/2015
Brown University
mi
from
Providence, RI
Click here to add this to my saved trials
ADvance DBS-f in Patients With Mild Probable Alzheimer's Disease
A Twelve Month Double-blind Randomized Controlled Feasibility Study to Evaluate the Safety, Efficacy and Tolerability of Deep Brain Stimulation of the Fornix (DBS-f) in Patients With Mild Probable Alzheimer's Disease
Status: Enrolling
Updated:  10/27/2015
Toronto Western Hospital
mi
from
Toronto,
ADvance DBS-f in Patients With Mild Probable Alzheimer's Disease
A Twelve Month Double-blind Randomized Controlled Feasibility Study to Evaluate the Safety, Efficacy and Tolerability of Deep Brain Stimulation of the Fornix (DBS-f) in Patients With Mild Probable Alzheimer's Disease
Status: Enrolling
Updated: 10/27/2015
Toronto Western Hospital
mi
from
Toronto,
Click here to add this to my saved trials
Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil
A Multi-Center Phase 1 Study of the Safety and Tolerability of Dimebon in Alzheimer's Disease Patients on Memantine (Cohort 1) and Memantine Plus Donepezil (Cohort 2)
Status: Enrolling
Updated:  11/6/2015
Clinical Research Facility
mi
from
Los Alamitos, CA
Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil
A Multi-Center Phase 1 Study of the Safety and Tolerability of Dimebon in Alzheimer's Disease Patients on Memantine (Cohort 1) and Memantine Plus Donepezil (Cohort 2)
Status: Enrolling
Updated: 11/6/2015
Clinical Research Facility
mi
from
Los Alamitos, CA
Click here to add this to my saved trials
Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil
A Multi-Center Phase 1 Study of the Safety and Tolerability of Dimebon in Alzheimer's Disease Patients on Memantine (Cohort 1) and Memantine Plus Donepezil (Cohort 2)
Status: Enrolling
Updated:  11/6/2015
Clinical Research Facility
mi
from
National City, CA
Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil
A Multi-Center Phase 1 Study of the Safety and Tolerability of Dimebon in Alzheimer's Disease Patients on Memantine (Cohort 1) and Memantine Plus Donepezil (Cohort 2)
Status: Enrolling
Updated: 11/6/2015
Clinical Research Facility
mi
from
National City, CA
Click here to add this to my saved trials
Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil
A Multi-Center Phase 1 Study of the Safety and Tolerability of Dimebon in Alzheimer's Disease Patients on Memantine (Cohort 1) and Memantine Plus Donepezil (Cohort 2)
Status: Enrolling
Updated:  11/6/2015
Clinical Research Facility
mi
from
Delray Beach, FL
Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil
A Multi-Center Phase 1 Study of the Safety and Tolerability of Dimebon in Alzheimer's Disease Patients on Memantine (Cohort 1) and Memantine Plus Donepezil (Cohort 2)
Status: Enrolling
Updated: 11/6/2015
Clinical Research Facility
mi
from
Delray Beach, FL
Click here to add this to my saved trials
Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil
A Multi-Center Phase 1 Study of the Safety and Tolerability of Dimebon in Alzheimer's Disease Patients on Memantine (Cohort 1) and Memantine Plus Donepezil (Cohort 2)
Status: Enrolling
Updated:  11/6/2015
Clinical Research Facility
mi
from
Orlando, FL
Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil
A Multi-Center Phase 1 Study of the Safety and Tolerability of Dimebon in Alzheimer's Disease Patients on Memantine (Cohort 1) and Memantine Plus Donepezil (Cohort 2)
Status: Enrolling
Updated: 11/6/2015
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's Disease
An Open-Label Extension Study of Combination Therapy With Dimebon and Donepezil in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  11/13/2015
Xenoscience Inc.
mi
from
Phoenix, AZ
Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's Disease
An Open-Label Extension Study of Combination Therapy With Dimebon and Donepezil in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 11/13/2015
Xenoscience Inc.
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's Disease
An Open-Label Extension Study of Combination Therapy With Dimebon and Donepezil in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  11/13/2015
Banner Alzheimer'S Institute
mi
from
Phoenix, AZ
Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's Disease
An Open-Label Extension Study of Combination Therapy With Dimebon and Donepezil in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 11/13/2015
Banner Alzheimer'S Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's Disease
An Open-Label Extension Study of Combination Therapy With Dimebon and Donepezil in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  11/13/2015
Barrow Neurological Institute
mi
from
Phoenix, AZ
Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's Disease
An Open-Label Extension Study of Combination Therapy With Dimebon and Donepezil in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 11/13/2015
Barrow Neurological Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's Disease
An Open-Label Extension Study of Combination Therapy With Dimebon and Donepezil in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  11/13/2015
Sun Health Research Institute
mi
from
Sun City, AZ
Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's Disease
An Open-Label Extension Study of Combination Therapy With Dimebon and Donepezil in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 11/13/2015
Sun Health Research Institute
mi
from
Sun City, AZ
Click here to add this to my saved trials
Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)
Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)
Status: Enrolling
Updated:  11/18/2015
Tuscaloosa VA Medical Center
mi
from
Tuscaloosa, AL
Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)
Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)
Status: Enrolling
Updated: 11/18/2015
Tuscaloosa VA Medical Center
mi
from
Tuscaloosa, AL
Click here to add this to my saved trials
Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)
Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)
Status: Enrolling
Updated:  11/18/2015
Tuscaloosa Veterans Affairs Medical Center
mi
from
Tuscaloosa, AL
Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)
Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)
Status: Enrolling
Updated: 11/18/2015
Tuscaloosa Veterans Affairs Medical Center
mi
from
Tuscaloosa, AL
Click here to add this to my saved trials
Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)
Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)
Status: Enrolling
Updated:  11/18/2015
VA Medical Center, Tuscaloosa
mi
from
Tuscaloosa, AL
Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)
Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)
Status: Enrolling
Updated: 11/18/2015
VA Medical Center, Tuscaloosa
mi
from
Tuscaloosa, AL
Click here to add this to my saved trials
Florbetapir Calibration to the Centiloid Scale
A Multicenter, Multicountry Study to Calibrate Florbetapir (18F) PET Imaging Data to the Centiloid Scale Based on 11C-PiB
Status: Enrolling
Updated:  11/25/2015
Clinical Research Facility
mi
from
Pittsburgh, PA
Florbetapir Calibration to the Centiloid Scale
A Multicenter, Multicountry Study to Calibrate Florbetapir (18F) PET Imaging Data to the Centiloid Scale Based on 11C-PiB
Status: Enrolling
Updated: 11/25/2015
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Florbetapir Calibration to the Centiloid Scale
A Multicenter, Multicountry Study to Calibrate Florbetapir (18F) PET Imaging Data to the Centiloid Scale Based on 11C-PiB
Status: Enrolling
Updated:  11/25/2015
Research Site
mi
from
Heidelberg,
Florbetapir Calibration to the Centiloid Scale
A Multicenter, Multicountry Study to Calibrate Florbetapir (18F) PET Imaging Data to the Centiloid Scale Based on 11C-PiB
Status: Enrolling
Updated: 11/25/2015
Research Site
mi
from
Heidelberg,
Click here to add this to my saved trials
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated:  11/30/2015
Banner Alzheimer'S Institute
mi
from
Phoenix, AZ
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated: 11/30/2015
Banner Alzheimer'S Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated:  11/30/2015
Banner Good Samaritan Medical Center
mi
from
Phoenix, AZ
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated: 11/30/2015
Banner Good Samaritan Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated:  11/30/2015
Banner Boswell Medical Center
mi
from
Sun City, AZ
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated: 11/30/2015
Banner Boswell Medical Center
mi
from
Sun City, AZ
Click here to add this to my saved trials
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated:  11/30/2015
Sun Health Research Institute
mi
from
Sun City, AZ
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated: 11/30/2015
Sun Health Research Institute
mi
from
Sun City, AZ
Click here to add this to my saved trials
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated:  11/30/2015
University of California at San Francisco
mi
from
San Francisco, CA
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated: 11/30/2015
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated:  11/30/2015
General Clinical Research Center
mi
from
New Haven, CT
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated: 11/30/2015
General Clinical Research Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated:  11/30/2015
Yale University School of Medicine
mi
from
New Haven, CT
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated: 11/30/2015
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated:  11/30/2015
Yale-New Haven Hospital
mi
from
New Haven, CT
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated: 11/30/2015
Yale-New Haven Hospital
mi
from
New Haven, CT
Click here to add this to my saved trials
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated:  11/30/2015
General Clinical Research Center
mi
from
Washington,
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated: 11/30/2015
General Clinical Research Center
mi
from
Washington,
Click here to add this to my saved trials
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated:  11/30/2015
GUMC
mi
from
Washington,
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated: 11/30/2015
GUMC
mi
from
Washington,
Click here to add this to my saved trials
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated:  11/30/2015
MD Clinical
mi
from
Hallandale Beach, FL
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated: 11/30/2015
MD Clinical
mi
from
Hallandale Beach, FL
Click here to add this to my saved trials
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated:  11/30/2015
Palm Beach Neurology and Premiere Research Institute
mi
from
West Palm Beach, FL
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated: 11/30/2015
Palm Beach Neurology and Premiere Research Institute
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated:  11/30/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated: 11/30/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated:  11/30/2015
Barnes Jewish Hospital
mi
from
St. Louis, MO
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated: 11/30/2015
Barnes Jewish Hospital
mi
from
St. Louis, MO
Click here to add this to my saved trials
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated:  11/30/2015
Washington University School of Medicine
mi
from
St. Louis, MO
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated: 11/30/2015
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated:  11/30/2015
Barrnes-Jewish Hospital at Washington University
mi
from
St. Louis, MO
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated: 11/30/2015
Barrnes-Jewish Hospital at Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated:  11/30/2015
Memory Enhancement Center of America, Inc.
mi
from
Eatontown, NJ
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated: 11/30/2015
Memory Enhancement Center of America, Inc.
mi
from
Eatontown, NJ
Click here to add this to my saved trials
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated:  11/30/2015
Pharmcare USA
mi
from
Edison, NJ
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated: 11/30/2015
Pharmcare USA
mi
from
Edison, NJ
Click here to add this to my saved trials
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated:  11/30/2015
Columbia Univ/Taub Institute Irving Ctr for Clinical Researc
mi
from
New York, NY
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated: 11/30/2015
Columbia Univ/Taub Institute Irving Ctr for Clinical Researc
mi
from
New York, NY
Click here to add this to my saved trials
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated:  11/30/2015
CUMC Research Pharmacy
mi
from
New York, NY
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated: 11/30/2015
CUMC Research Pharmacy
mi
from
New York, NY
Click here to add this to my saved trials
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated:  11/30/2015
Butler Hospital
mi
from
Providence, RI
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated: 11/30/2015
Butler Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated:  11/30/2015
The Memory Clinic
mi
from
Bennington, VT
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated: 11/30/2015
The Memory Clinic
mi
from
Bennington, VT
Click here to add this to my saved trials
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated:  11/30/2015
The Pharmacy; Inc.
mi
from
Bennington, VT
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
Status: Enrolling
Updated: 11/30/2015
The Pharmacy; Inc.
mi
from
Bennington, VT
Click here to add this to my saved trials
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.
Status: Enrolling
Updated:  11/30/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.
Status: Enrolling
Updated: 11/30/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.
Status: Enrolling
Updated:  11/30/2015
UAB Center for Psychiatric Medicine
mi
from
Birmingham, AL
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.
Status: Enrolling
Updated: 11/30/2015
UAB Center for Psychiatric Medicine
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.
Status: Enrolling
Updated:  11/30/2015
Dedicated Clinical Research
mi
from
Goodyear, AZ
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.
Status: Enrolling
Updated: 11/30/2015
Dedicated Clinical Research
mi
from
Goodyear, AZ
Click here to add this to my saved trials
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.
Status: Enrolling
Updated:  11/30/2015
Banner Alzheimer'S Institute
mi
from
Phoenix, AZ
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.
Status: Enrolling
Updated: 11/30/2015
Banner Alzheimer'S Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.
Status: Enrolling
Updated:  11/30/2015
Banner Good Samaritan Medical Center (Imaging
mi
from
Phoenix, AZ
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.
Status: Enrolling
Updated: 11/30/2015
Banner Good Samaritan Medical Center (Imaging
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.
Status: Enrolling
Updated:  11/30/2015
Jeffrey S. Gitt
mi
from
Phoenix, AZ
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.
Status: Enrolling
Updated: 11/30/2015
Jeffrey S. Gitt
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.
Status: Enrolling
Updated:  11/30/2015
HOPE Research Institute
mi
from
Phoenix, AZ
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.
Status: Enrolling
Updated: 11/30/2015
HOPE Research Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.
Status: Enrolling
Updated:  11/30/2015
Clinical Trials, Inc.
mi
from
Little Rock, AR
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.
Status: Enrolling
Updated: 11/30/2015
Clinical Trials, Inc.
mi
from
Little Rock, AR
Click here to add this to my saved trials